LNK01001
Phase 3Small molecule
LNK01001 is one of 104 small molecule programs targeting Rheumatoid Arthritis. It is currently in Phase 3.
3
Indications
6
Total Trials
3
Active Trials
103
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
791 competitors in Rheumatoid Arthritis
#DrugCompanyPhaseTrials
1Orencia
Bristol-Myers SquibbPreclinical
Cimzia
UCBPreclinical
LNK01001
LLynk Pharmaceuticals Co., Ltd
Phase 3
Simponi
Johnson & JohnsonPreclinical
Enbrel
IImmunex
Preclinical
Remicade
OOrganon and Co
Preclinical
Arcoxia
NovartisPreclinical
Celexa
AbbViePreclinical
Kineret
SSwedish Orphan Biovitrum
Preclinical
Rituxan
PfizerPreclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Atopic Dermatitis2 trials
Ankylosing Spondylitis2 trials
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for LNK01001. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 3[1]
- Company
- LLynk Pharmaceuticals Co., Ltd